The pharmacology of cannabinoid receptors and their ligands

an overview

Research output: Contribution to journalArticle

303 Citations (Scopus)

Abstract

Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB, receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachiclonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance, autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.

Original languageEnglish
Pages (from-to)S13–S18
Number of pages6
JournalInternational Journal of Obesity
Volume30
Issue numberSupplement 1
DOIs
Publication statusPublished - 2006

Keywords

  • cannabinoid CB1 and CB2 receptors
  • endocannabinoids
  • autoprotection and autoimpairment
  • cannabinoid receptor inverse agonists and neutral antagonists
  • allosteric site
  • therapeutic targets and strategies
  • overweight patients
  • inverse agonist
  • CB1 receptor
  • risk factors
  • arachidonyl-2-chloroethylamide
  • modulation
  • rimonabant
  • responses
  • currents
  • brain

Cite this

The pharmacology of cannabinoid receptors and their ligands : an overview. / Pertwee, Roger Guy.

In: International Journal of Obesity, Vol. 30, No. Supplement 1, 2006, p. S13–S18.

Research output: Contribution to journalArticle

@article{b7b9a1d3e2f74eab8808b2fd8ee0a32c,
title = "The pharmacology of cannabinoid receptors and their ligands: an overview",
abstract = "Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB, receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachiclonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance, autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.",
keywords = "cannabinoid CB1 and CB2 receptors, endocannabinoids, autoprotection and autoimpairment, cannabinoid receptor inverse agonists and neutral antagonists, allosteric site, therapeutic targets and strategies, overweight patients, inverse agonist, CB1 receptor, risk factors, arachidonyl-2-chloroethylamide, modulation, rimonabant, responses, currents, brain",
author = "Pertwee, {Roger Guy}",
year = "2006",
doi = "10.1038/sj.ijo.0803272",
language = "English",
volume = "30",
pages = "S13–S18",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "Supplement 1",

}

TY - JOUR

T1 - The pharmacology of cannabinoid receptors and their ligands

T2 - an overview

AU - Pertwee, Roger Guy

PY - 2006

Y1 - 2006

N2 - Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB, receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachiclonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance, autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.

AB - Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB, receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachiclonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance, autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.

KW - cannabinoid CB1 and CB2 receptors

KW - endocannabinoids

KW - autoprotection and autoimpairment

KW - cannabinoid receptor inverse agonists and neutral antagonists

KW - allosteric site

KW - therapeutic targets and strategies

KW - overweight patients

KW - inverse agonist

KW - CB1 receptor

KW - risk factors

KW - arachidonyl-2-chloroethylamide

KW - modulation

KW - rimonabant

KW - responses

KW - currents

KW - brain

U2 - 10.1038/sj.ijo.0803272

DO - 10.1038/sj.ijo.0803272

M3 - Article

VL - 30

SP - S13–S18

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - Supplement 1

ER -